Chromosome 8q24.1/c-MYC abnormality: A marker for high-risk myeloma

Leukemia and Lymphoma

Volumn 56, Issue 3, 2015, Pages 602-607

  Glitza, Isabella C ^a   Lu, Gary ^a   Shah, Rupin ^a   Bashir, Qaiser ^a   Shah, Nina ^a   Champlin, Richard E ^a   Shah, Jatin ^a   Orlowski, Robert Z ^a   Qazilbash, Muzaffar H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

c MYC 8q24; high risk; multiple myeloma; plasma cell leukemia

Indexed keywords

MYC PROTEIN; TUMOR MARKER;

ADULT; AGED; CHROMOSOME 8; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PATHOLOGY; PHYSIOLOGY; PLASMA CELL LEUKEMIA; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GENE REARRANGEMENT; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84924718744     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.924116     Document Type: Article

References (30)

1. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118:3205-3211.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007;82:323-341.
4. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-1558.
5. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-4700.
6. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84:1095-1110.
7. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529-534.
8. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226-235.
9. Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med 2008;8:446-458.
10. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene 2008;27:6462-6472.
11. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082-3086.
12. Holien T, Sundan A. Oncogene addiction to c-MYC in myeloma cells. Oncotarget 2012;3:739-740.
13. Tonon G. Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 2007;21:985-1006, vii.
14. Chiecchio L, Dagrada GP, Protheroe RK, et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009;94:1024-1028.
15. Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 2009;48:624-636.
16. Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013;27:780-791.
17. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, et al. Plasmablastic lymphoma with MYC translocation:evidence for a common pathway in the generation of plasmablastic features. Mod Pathol 2010;23:991-999.
18. Billecke L, Murga Penas EM, May AM, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 2013;161:87-94.
19. Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma:incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011;29:3805-3812.
20. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
22. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005;130:662-670.
23. Delgado MD, Leon J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010;1:605-616.
24. Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011;17:1253-1263.
25. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study. Lancet 2010;376:2075-2085.
26. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010;115:4168-4173.
27. Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121:884-892.
28. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma:the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-3495.
29. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940-948.
30. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-2955.